Webinar | November 15, 2023

Adopting Novel Technologies To Improve Monoclonal Antibody Processes

Source: Avantor

New bispecific antibodies show better cancer-fighting promise as compared to traditional monoclonal antibodies, but they can create process difficulties. Avantor’s Dr. Nandu Deokar talks about four new-edge production technologies that better remove impurities, reduce aggregation and improve stability; including viral inactivation that overcomes REACH concerns, newly designed chromatography ligand, additives in wash step and novel excipients in formulation buffer.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online